Unconfigured Ad

Collapse
X
Collapse
 
  • Page of 1
  • Filter
  • Time
  • Show
Clear All
new posts
Previous template Next
  • JoshLowth
    Junior Member
    • Apr 2012
    • 4
    #1

    CDx success insights from Xalkori and Zelboraf

    4th Molecular Diagnostics for Cancer Drug Development
    Meet the oncology and diagnostics experts you need to deliver better, safer drugs to market quicker
    25 - 28 June 2012, Boston
    www.moleculardiagnostics-cancer.com

    Featuring 31 expert speakers, including:
    • Dr Richard Buller, Vice President, Translational Oncology, Pfizer
    • Dr Miu Chau, Global Head, Companion Diagnostics Operations, Genentech
    • Dr Mitch Raponi, Senior Director, Molecular Diagnostics & Translational Medicine, Clovis Oncology


    This meeting will profile those at the cutting edge of personalized medicine in oncology to give you a thorough review of best practice in end to end drug and diagnostic development from discovery to commercialization.

    For more information please visit the website: www.moleculardiagnostics-cancer.com or get in touch on [email protected].

    Josh Lowth
    Hanson Wade
    Tags: companion diagnostics, molecular diagnostics, oncology, personalized medicine
Previous template Next

Latest Articles

Collapse
  • GATTACAT
    Reply to Nine Things a Sample Prep Scientist Thinks About Before Sequencing
    by GATTACAT
    Love this - good data definitely starts from good input, and poor input can only give relatively poor data. I particularly like the mention of Nanodrop/absorbance based methods for quantification. It's such a toss up if you'll get an accurate reading or what amounts to a randomly generated number, and a lot of library/sequencing related issues can be traced back to poor quant.
    07-01-2026, 11:43 AM
  • SEQadmin2
    Nine Things a Sample Prep Scientist Thinks About Before Sequencing
    by SEQadmin2


    I’m not a sequencing expert. I’m a purification scientist who uses NGS to evaluate workflows my group develops. With this perspective, we think about the sample first and the NGS workflow second. The sequencer is an exceptionally honest reporter, but it can only report on what you give it, so whether you get clean, interpretable data from an NGS workflow is largely determined before you begin.

    Here are nine questions we think about, in roughly the order they matter, before...
    06-18-2026, 07:11 AM
View All

ad_right_rmr

Collapse

News

Collapse
Topics Statistics Last Post
High-Resolution Sequencing Exposes Hidden Toxoplasma Diversity by SEQadmin2
Started by SEQadmin2, Yesterday, 11:08 AM
0 responses
6 views
0 reactions
 Last Post SEQadmin2
by SEQadmin2
Yesterday, 11:08 AM  
New AI Model Captures Long-Range Genomic Signals to Improve RNA Splice Site Prediction by SEQadmin2
Started by SEQadmin2, 06-30-2026, 05:37 AM
0 responses
11 views
0 reactions
 Last Post SEQadmin2
by SEQadmin2
06-30-2026, 05:37 AM  
Large-Scale Protein Screen Uncovers Hidden Regulators of Alternative Polyadenylation by SEQadmin2
Started by SEQadmin2, 06-26-2026, 11:10 AM
0 responses
19 views
0 reactions
 Last Post SEQadmin2
by SEQadmin2
06-26-2026, 11:10 AM  
Whole-Genome Sequencing Traces Faroe Islands Ancestry to a North Atlantic Founder Population by SEQadmin2
Started by SEQadmin2, 06-17-2026, 06:09 AM
0 responses
53 views
0 reactions
 Last Post SEQadmin2
by SEQadmin2
06-17-2026, 06:09 AM  
View All
Working...